ProCE Banner Activity

Neoadjuvant ICI Therapy for Bladder Cancer: My Thoughts on Where We Stand Today

Clinical Thought
Are you aware of promising new options in clinical trials for your patients with bladder cancer who cannot receive cisplatin? Read my thoughts on the potential roles of neoadjuvant pembrolizumab and atezolizumab.

Released: September 10, 2018

Expiration: September 09, 2019

No longer available for credit.

Share

Faculty

Matthew I. Milowsky

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Matthew I. Milowsky, MD, has disclosed that he has received funds for research support from Acerta, BioClin, Bristol-Myers Squibb, Cerulean, Incyte, Innocrin, Inovio, MedImmune, Merck, Mirati, Pfizer, Roche/Genentech, Seattle Genetics, and X4 Pharma.